Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JANX011 in Healthy Adult Volunteers
NCT07291323Phase 1Recruiting
- Sponsor
- Janux Therapeutics
- Start
- Feb 2026
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JANX011 in autoimmune disease, sponsored by Janux Therapeutics. Primary endpoint: Incidence, severity, and relatedness of Treatment-Emergent Adverse Events up to 85 days. Started Feb 2026; status: recruiting.
02
Drugs
JANX011
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07291323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07291323.